Adamas Announces Issuance of New U.S. Patent Covering GOCOVRI

- December 19th, 2018

Adamas Pharmaceuticals (Nasdaq:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that a new patent has been issued that covers GOCOVRI (amantadine) extended release capsules by the United States Patent and Trademark Office (USPTO). As quoted in the press release: Patent No. 10,154,971 (“the ’971 Patent”) claims a method … Continued

Adamas Pharmaceuticals (Nasdaq:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that a new patent has been issued that covers GOCOVRI (amantadine) extended release capsules by the United States Patent and Trademark Office (USPTO).

As quoted in the press release:

Patent No. 10,154,971 (“the ’971 Patent”) claims a method of reducing OFF time in a patient with Parkinson’s disease and is the first patent to issue from this patent family. The USPTO has now issued a total of 14 patents from three separate patent families in the GOCOVRI patent portfolio, which now has patents expiring from 2025 to 2034.  The ‘971 patent will be listed in the U.S. Food and Drug Administration’s (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.

Click here to read the full press release.

Find out what experts are saying about the future of cannabis

 
Read our 2019 conference report today
 

Leave a Reply